2024年1月18日,以色列Weizmann科学研究所的研究人员在Cell期刊发表了题为:Bispecific dendritic-T cell engager potentiates anti-tumor immunity的研究文章。 1.背景 使用抗PD-1(aPD-1)单克隆抗体的免疫检查点抑制治疗是一种有前景的癌症免疫治疗方法。然而,它对肿瘤免疫的影响范围较窄,因为大多数患者对该治疗没有反...
在这一发现的基础上,研究团队开发了一种双特异性树突状细胞-T细胞接合剂(Bispecific DC-T Cell Engager,BiCE)双抗,促进PD-1+T细胞和cDC1之间物理相互作用,该双抗的两个抗体臂分别连接两种不同细胞,一个与T细胞(CD8)结合,靶向PD-1,另一个树突状细胞(cDC1)结合,靶向CLEC9A。 在创造了这种BiCE双抗后,研究团队...
求翻译:Bispecific T cell-engager是什么意思?待解决 悬赏分:1 - 离问题结束还有 Bispecific T cell-engager问题补充:匿名 2013-05-23 12:21:38 双特异性T细胞接合 匿名 2013-05-23 12:23:18 (Bispecific T细胞允诺 匿名 2013-05-23 12:24:58 Bispecific T隐含对参与 匿名 2013-05-23 12:26:...
Thomas G. Martin, MD:We have been part of the Celgene trial for their bispecific T-cell engager. And it was presented by Dr [Luciano] Costa at ASH. They did a first-in-human dose-escalation trial, then they treated 9 patients at what they believe is going to be the dose. They took...
Bispecific T-cell engager (BiTE) immunotherapy is a promising therapy for cancer treatment. However, the high cost and short life-time in vivo of the BiTE limit its wide clinical application. Here, we built for the first time a gene delivery system based on MIL-88A metal organic framework ...
AMG 420 (Amgen) is a bispecific T-cell engager that targets theB-cell maturation antigenon multiple myeloma cells and CD3 on T cells. “In this first-in-human study, AMG 420 — a short half-life bispecific T-cell engager ...
Teclistamab-cqyv (Tecvayli) was approved in 2022 as the first bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager to be indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior lines of therapy, including...
Harnessing the power of immune cells, especially T cells, to enhance anti-tumor activities has become a promising strategy in clinical management of hematologic malignancies. The emerging bispecific antibodies (BsAbs), which recruit T cells to tumor cells, exemplified by bispecific T cell engagers (...
The novel bispecific T-cell engager (BiTE) with an additional hIgFc (BiTE-hIgFc, STL001) can target T cells, natural killer cells, and multiple myeloma cells (RPMI-8226 or U266). In addition, BiTE-hIgFc (STL001) has nanomolar-level affinity to recombinant human CD138 protein and shows...
Elranatamab (elranatamab-bcmm; ELREXFIO) is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T cell engager being developed by Pfizer for the treatment of multiple myeloma (MM). Elranatamab bridges CD3 on T cells with BCMA expr... S Dhillon - 《Drugs》 被引量: 0发表: 202...